Key result
Rate control remains common first-line AF therapy despite failing to prevent progression or relieve severe symptoms.
Why the study?
Primary management of AF through rate control or rhythm control remains debated, and several issues regarding first-line rate control strategies remain debatable.
Rate control remains a widely used first-line management strategy for atrial fibrillation to alleviate symptoms and improve quality of life, despite ongoing debates regarding its efficacy in preventing disease progression.
Supports continued first-line rate control in AF; leaves open targeted trials for progression and severe symptoms.
Atrial fibrillation (AF) is one of the main cardiac arrhythmias associated with higher risk of cardiovascular morbidity and mortality. AF can cause adverse symptoms and reduced quality of life. One of the strategies for the management of AF is rate control, which can modulate ventricle rate, alleviate adverse associated symptoms and improve the quality of life. As primary management of AF through rate control or rhythm is a topic under debate, the purpose of this review is to explore the rationale for the rate control approach in managing AF by considering the guidelines, recommendations and determinants for the choice of rate control drugs, including beta blockers, digoxin and non- dihydropyridine calcium channel blockers for patients with AF and other comorbidities and atrioventricular nodal ablation and pacing. Despite the limitations of rate control treatment, which may not be effective in preventing disease progression or in reducing symptoms in highly symptomatic patients, it is widely used for almost all patients with atrial fibrillation. Although rate control is one of the first line management of all patient with atrial fibrillation, several issues remain debateable.
No takes yet. Share an insight, caveat, or question.
Alobaida et al. (2021) conducted a review in Atrial fibrillation. Rate control strategies was evaluated. Rate control strategies remain a widely used first-line management for atrial fibrillation, despite limitations in preventing disease progression or reducing symptoms in highly symptomatic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: